Pharmaceutical Companies

Under the agreement, Everest Medicines will receive US$112.5 million upfront from Travere Therapeutics and could earn up to US$1.03 billion more in milestone payments if certain clinical, regulatory, and commercial goals are met across five indications.

The financing round was co-led by M Ventures, the venture capital arm of Merck KGaA, and GordonMD Global Investments.

Astex will also qualify for development, regulatory, and commercial milestone payments exceeding US$465 million, totaling US$490 million with the upfront payment included.

Founded in 2019 as a spinout from Imperial College London and the Francis Crick Institute, Myricx has attracted strong investor backing and has emerged as one of the UK’s leading oncology biotechnology companies.

Under the definitive agreement, which both companies’ boards unanimously approved, Vertex will pay US$85.00 in cash for each outstanding Crinetics share.

Tregzi, also known as Orca-T, is an engineered allogeneic cell therapy used alongside matched-donor hematopoietic stem cell transplantation.

The acquisition centres on potravitug, a Phase II monoclonal antibody developed to treat BK polyomavirus-associated nephropathy (BKPyVAN).

The company has announced plans to expand its antibody-drug conjugate (ADC) manufacturing capabilities in Switzerland while also broadening its long-term partnership with a leading, though undisclosed, U.S.-based biopharmaceutical company.

Under the collaboration, Insilico Medicine will use its proprietary Pharma.AI platform to identify and optimise drug candidates that meet predefined scientific and early development criteria.

Verzenios is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor developed by Lilly for the treatment of several forms of breast cancer.